Cargando…
Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients
Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate t...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094652/ https://www.ncbi.nlm.nih.gov/pubmed/21380717 http://dx.doi.org/10.1007/s00246-011-9928-5 |
_version_ | 1782203587070263296 |
---|---|
author | Scott, Victoria Williams, Ryan J. Levi, Daniel S. |
author_facet | Scott, Victoria Williams, Ryan J. Levi, Daniel S. |
author_sort | Scott, Victoria |
collection | PubMed |
description | Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate the outcomes of transplant candidates stratified by PRA values. Records of pediatric patients listed for OHT between April 2004 and July 2008 were reviewed (n = 101). Survival analysis was performed comparing patients with PRA < 25 to those with PRA > 25, as well as patients with PRA < 80 and PRA > 80. Patients with PRA > 25 had decreased survival compared with those with PRA < 25 after listing (P = 0.004). There was an even greater difference in survival between patients with PRA > 80 and those with PRA < 80 (P = 0.002). Similar analyses for the patients who underwent successful transplantation showed no significant difference in post-transplant survival between patients with a pre-transplant PRA > 25 and those with PRA < 25 (P = 0.23). A difference approaching significance was noted for patients with PRA > 80 compared with PRA < 80 (P = 0.066). Patients with significantly elevated pre-transplant PRAs at the time of listing have a significantly worse outcome compared to those with moderately increased PRA values or non-sensitized patients. Further study is necessary to guide physician and family treatment decisions at the time of listing. |
format | Text |
id | pubmed-3094652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-30946522011-07-07 Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients Scott, Victoria Williams, Ryan J. Levi, Daniel S. Pediatr Cardiol Original Article Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate the outcomes of transplant candidates stratified by PRA values. Records of pediatric patients listed for OHT between April 2004 and July 2008 were reviewed (n = 101). Survival analysis was performed comparing patients with PRA < 25 to those with PRA > 25, as well as patients with PRA < 80 and PRA > 80. Patients with PRA > 25 had decreased survival compared with those with PRA < 25 after listing (P = 0.004). There was an even greater difference in survival between patients with PRA > 80 and those with PRA < 80 (P = 0.002). Similar analyses for the patients who underwent successful transplantation showed no significant difference in post-transplant survival between patients with a pre-transplant PRA > 25 and those with PRA < 25 (P = 0.23). A difference approaching significance was noted for patients with PRA > 80 compared with PRA < 80 (P = 0.066). Patients with significantly elevated pre-transplant PRAs at the time of listing have a significantly worse outcome compared to those with moderately increased PRA values or non-sensitized patients. Further study is necessary to guide physician and family treatment decisions at the time of listing. Springer-Verlag 2011-03-06 2011 /pmc/articles/PMC3094652/ /pubmed/21380717 http://dx.doi.org/10.1007/s00246-011-9928-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Scott, Victoria Williams, Ryan J. Levi, Daniel S. Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title | Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title_full | Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title_fullStr | Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title_full_unstemmed | Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title_short | Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients |
title_sort | outcomes of cardiac transplantation in highly sensitized pediatric patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094652/ https://www.ncbi.nlm.nih.gov/pubmed/21380717 http://dx.doi.org/10.1007/s00246-011-9928-5 |
work_keys_str_mv | AT scottvictoria outcomesofcardiactransplantationinhighlysensitizedpediatricpatients AT williamsryanj outcomesofcardiactransplantationinhighlysensitizedpediatricpatients AT levidaniels outcomesofcardiactransplantationinhighlysensitizedpediatricpatients |